NCT04997382View on ClinicalTrials.gov

Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Chemotherapy alone or Chemotherapy plus Immune Checkpoint Inhibitors with or without Bevacizumab

Immune Checkpoint Inhibitors, for pembrolizumab, 200mg ivgtt once,every 21 days; for Atezolizumab, 1200mg vgtt once,every 21 days.

DRUG

Chemotherapy alone or Chemotherapy with or without Bevacizumab

Bevacizumab, 15mg/kg，every 21 day

Trial Locations (1)

410013

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER

NCT04997382 - Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC | Biotech Hunter | Biotech Hunter